These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

321 related items for PubMed ID: 31006179

  • 21. Species distribution and antifungal susceptibility of 358 Trichosporon clinical isolates collected in 24 medical centres.
    Francisco EC, de Almeida Junior JN, de Queiroz Telles F, Aquino VR, Mendes AVA, de Andrade Barberino MGM, de Tarso O Castro P, Guimarães T, Hahn RC, Padovan ACB, Chaves GM, Colombo AL.
    Clin Microbiol Infect; 2019 Jul; 25(7):909.e1-909.e5. PubMed ID: 30991116
    [Abstract] [Full Text] [Related]

  • 22. Chemoport-related Fungemia Caused by Trichosporon asahii.
    Raju DS, Sugunan A, Keechilattu P, Philip A, Reghu R.
    J Pediatr Hematol Oncol; 2020 Apr; 42(3):e193-e194. PubMed ID: 30676435
    [Abstract] [Full Text] [Related]

  • 23. Multiple species of Trichosporon produce biofilms highly resistant to triazoles and amphotericin B.
    Iturrieta-González IA, Padovan AC, Bizerra FC, Hahn RC, Colombo AL.
    PLoS One; 2014 Apr; 9(10):e109553. PubMed ID: 25360765
    [Abstract] [Full Text] [Related]

  • 24. Intergenic spacer (IGS-1) region sequence-based identification, genotypic analysis, and antifungal susceptibility of clinical Trichosporon species.
    Parashar A, Rastogi V, Prakash H, Pandey A, Rudramurthy SM.
    Indian J Med Microbiol; 2023 Apr; 45():100390. PubMed ID: 37573054
    [Abstract] [Full Text] [Related]

  • 25. Trichosporon asahii as a prospective pathogen in solid organ transplant recipients.
    Netsvyetayeva I, Swoboda-Kopeć E, Paczek L, Fiedor P, Sikora M, Jaworska-Zaremba M, Blachnio S, Luczak M.
    Mycoses; 2009 May; 52(3):263-5. PubMed ID: 18705664
    [Abstract] [Full Text] [Related]

  • 26. [An overview on Trichosporon asahii and its infections].
    Hazırolan G.
    Mikrobiyol Bul; 2012 Oct; 46(4):707-15. PubMed ID: 23188586
    [Abstract] [Full Text] [Related]

  • 27. Isolation and antifungal susceptibility testing of Trichosporon asahii in Ceará, Brazil.
    Menezes EA, Marinho JA, Angelo MR, Cunha Mda C, Cunha FA, Vasconcelos Júnior AA.
    Rev Inst Med Trop Sao Paulo; 2012 Oct; 54(1):1-3. PubMed ID: 22370746
    [Abstract] [Full Text] [Related]

  • 28. Biofilm formation by the emerging fungal pathogen Trichosporon asahii: development, architecture, and antifungal resistance.
    Di Bonaventura G, Pompilio A, Picciani C, Iezzi M, D'Antonio D, Piccolomini R.
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3269-76. PubMed ID: 17005804
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. A novel silkworm infection model with fluorescence imaging using transgenic Trichosporon asahii expressing eGFP.
    Matsumoto Y, Yamazaki H, Yamasaki Y, Tateyama Y, Yamada T, Sugita T.
    Sci Rep; 2020 Jul 03; 10(1):10991. PubMed ID: 32620930
    [Abstract] [Full Text] [Related]

  • 32. Fatal disseminated Trichosporon asahii fungemia in a child with acute lymphoblastic leukemia and a morbilliform eruption.
    Nguyen JK, Schlichte MJ, Schady D, Pourciau CY.
    Pediatr Dermatol; 2018 Jan 03; 35(1):e86-e87. PubMed ID: 29266471
    [Abstract] [Full Text] [Related]

  • 33. Susceptibilities to amphotericin B, fluconazole and voriconazole of Trichosporon clinical isolates.
    Tsai MS, Yang YL, Wang AH, Wang LS, Lu DC, Liou CH, Hsieh LY, Wu CJ, Cheng MF, Shi ZY, Lo HJ.
    Mycopathologia; 2012 Aug 03; 174(2):121-30. PubMed ID: 22318636
    [Abstract] [Full Text] [Related]

  • 34. Biofilm formation and antifungal susceptibility of Trichosporon asahii isolates from Mexican patients.
    Montoya AM, Elizondo-Zertuche M, Treviño-Rangel RJ, Becerril-García M, González GM.
    Rev Iberoam Micol; 2018 Aug 03; 35(1):22-26. PubMed ID: 29287630
    [Abstract] [Full Text] [Related]

  • 35. Trichosporon asahii sepsis in a patient with pediatric malignancy.
    Ozkaya-Parlakay A, Karadag-Oncel E, Cengiz AB, Kara A, Yigit A, Gucer S, Gur D.
    J Microbiol Immunol Infect; 2016 Feb 03; 49(1):146-9. PubMed ID: 23419599
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. In vitro combined activity of amphotericin B, caspofungin and voriconazole against clinical isolates of Trichosporon asahii.
    Li H, Lu Q, Wan Z, Zhang J.
    Int J Antimicrob Agents; 2010 Jun 03; 35(6):550-2. PubMed ID: 20202797
    [Abstract] [Full Text] [Related]

  • 39. Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole.
    Antachopoulos C, Papakonstantinou E, Dotis J, Bibashi E, Tamiolaki M, Koliouskas D, Roilides E.
    J Pediatr Hematol Oncol; 2005 May 03; 27(5):283-5. PubMed ID: 15891566
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.